Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Through an Individualized Nutritionnal Approach and Semaglutide Therapy.

NCT06764056 is registered in ClinicalTrials.gov with Institut universitaire de cardiologie et de pneumologie de Québec, University Laval as lead sponsor.

NCT NCT06764056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06764056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Through an Individualized Nutritionnal Approach and Semaglutide Therapy.
Lead sponsor
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Phase
Not applicable
Overall status
Not yet recruiting
Start date
January 31, 2025
Completion date
May 31, 2026
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic associated fatty liver disease, metabolic associated-dysfunction steatohepatitis (mash), obesity